{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:49Z","timestamp":1785265129175,"version":"3.55.0"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hunan Provincial Natural Science Foundation of Science and Medicine Joint Fund","award":["2022JJ80040"],"award-info":[{"award-number":["2022JJ80040"]}]},{"name":"Hunan Provincial Health Commission Project","award":["202213053462"],"award-info":[{"award-number":["202213053462"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2023JJ60094"],"award-info":[{"award-number":["2023JJ60094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (SLE) in China. However, the economic value of these two drugs is unclear. Therefore, this study aims to evaluate the cost-effectiveness of telitacicept versus belimumab in SLE from the perspective of Chinese society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The network meta-analysis (NMA) and cost-effectiveness analysis included the efficacy and safety of patients from five randomised clinical trials. A microsimulation model was constructed to compare the cost-effectiveness of telitacicept versus belimumab in SLE. The model integrated short-term efficacy and long-term prognosis to simulate the patient\u2019s lifetime. Outcome measures included life years (LYs), quality-adjusted LYs (QALYs), total healthcare costs and the incremental cost-effectiveness ratio (ICER). The robustness of the model was assessed through sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NMA suggested the response rate risk ratios (RRs) of telitacicept compared with belimumab were 1.200 (95% CI 0.760 to 1.910). When this RR was used as the model input, the results of the baseline analysis showed an increase in the effectiveness of 0.506 QALYs and an increase in the total cost of US$3026 for telitacicept as compared with belimumab, with an ICER of US$5984 per QALY gained. At a willingness-to-pay (WTP) threshold of US$40 344 per QALY, the probability that telitacicept would be cost-effective compared with belimumab was 99.1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the comparative efficacy between telitacicept and belimumab remains statistically inconclusive, cost-effectiveness modelling suggests that telitacicept plus standard therapy is likely to be a cost-effective treatment option for patients with SLE in China under current WTP thresholds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001684","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:10:51Z","timestamp":1768590651000},"page":"e001684","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Telitacicept versus belimumab for the treatment of systemic lupus erythematosus: a network meta-analysis and cost-effectiveness analysis"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02885610","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Li","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dou","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0975-1962","authenticated-orcid":false,"given":"Zhenhua","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026072811150705000_13.1.e001684.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.06.003"},{"key":"2026072811150705000_13.1.e001684.2","first-page":"905","article-title":"Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial","volume":"23","author":"Fiechtner","year":"2014","journal-title":"Lupus (Los Angel)"},{"key":"2026072811150705000_13.1.e001684.3","doi-asserted-by":"crossref","DOI":"10.1186\/ar2368","article-title":"Rheumatic diseases in China","volume":"10","author":"Zeng","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2026072811150705000_13.1.e001684.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260"},{"key":"2026072811150705000_13.1.e001684.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211663"},{"key":"2026072811150705000_13.1.e001684.6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/13696998.2017.1362411","article-title":"Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis","volume":"20","author":"Wu","year":"2017","journal-title":"J Med Econ"},{"key":"2026072811150705000_13.1.e001684.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"2026072811150705000_13.1.e001684.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022491"},{"key":"2026072811150705000_13.1.e001684.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket120"},{"key":"2026072811150705000_13.1.e001684.10","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2016.1276903"},{"key":"2026072811150705000_13.1.e001684.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026072811150705000_13.1.e001684.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026072811150705000_13.1.e001684.13","first-page":"1671","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026072811150705000_13.1.e001684.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854"},{"key":"2026072811150705000_13.1.e001684.15","first-page":"S116","article-title":"Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider","volume":"30","author":"Turchetti","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026072811150705000_13.1.e001684.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.24063"},{"key":"2026072811150705000_13.1.e001684.17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/lupus-2021-000503","article-title":"Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015","volume":"8","author":"Jiang","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026072811150705000_13.1.e001684.18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/lupus-2021-000504","article-title":"Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015","volume":"8","author":"Hammond","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026072811150705000_13.1.e001684.19","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11136-020-02572-9","article-title":"Patient-reported flare frequency is associated with diminished quality of life and family role functioning in systemic lupus erythematosus","volume":"29","author":"Katz","year":"2020","journal-title":"Qual Life Res"},{"key":"2026072811150705000_13.1.e001684.20","first-page":"275","article-title":"Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden","volume":"26","author":"Katz","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2026072811150705000_13.1.e001684.21","unstructured":"Cochrane training. Cochrane RevMan, Available: https:\/\/training.cochrane.org\/online-learning\/core-software [Accessed 16 Jan 2025]."},{"key":"2026072811150705000_13.1.e001684.22","unstructured":"Research. CCfHE: China Center for Health Economic Research. China guidelines forpharmacoeconomic evaluations (Version 2011) [in Chinese], 2011. Available: https:\/\/tools.ispor.org\/peguidelines\/ [Accessed 13 Jan 2025]."},{"key":"2026072811150705000_13.1.e001684.23","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O"},{"key":"2026072811150705000_13.1.e001684.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026072811150705000_13.1.e001684.25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.vhri.2023.03.007","article-title":"Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study","volume":"37","author":"He","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"2026072811150705000_13.1.e001684.26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121368"},{"key":"2026072811150705000_13.1.e001684.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140843","article-title":"Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis","volume":"10","author":"Pierotti","year":"2015","journal-title":"PLoS One"},{"key":"2026072811150705000_13.1.e001684.28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40744-021-00308-w","article-title":"Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China","volume":"8","author":"Li","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2026072811150705000_13.1.e001684.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu375"},{"key":"2026072811150705000_13.1.e001684.30","unstructured":"Organization. WH: Global Health Observatory data repository: Life tables by country China, Available: https:\/\/apps.who.int\/gho\/data\/view.main.60340 [Accessed 12 Jan 2025]."},{"key":"2026072811150705000_13.1.e001684.31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00296-016-3551-y","article-title":"Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study","volume":"36","author":"Chiu","year":"2016","journal-title":"Rheumatol Int"},{"key":"2026072811150705000_13.1.e001684.32","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.3390\/ijerph20043522","article-title":"Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry","volume":"20","author":"Wang","year":"2023","journal-title":"IJERPH"},{"key":"2026072811150705000_13.1.e001684.33","unstructured":"China nboso. National bureau of statistics of china, Available: http:\/\/data.stats.gov.cn\/english\/index.htm [Accessed 24 Jan 2025]."},{"key":"2026072811150705000_13.1.e001684.34","doi-asserted-by":"crossref","first-page":"11382","DOI":"10.21037\/apm-21-2412","article-title":"Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China","volume":"10","author":"Wang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026072811150705000_13.1.e001684.35","unstructured":"The people\u2019s bank of china. Exchange rate, Available: http:\/\/www.pbc.gov.cn [Accessed 13 Jan 2025]."},{"key":"2026072811150705000_13.1.e001684.36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12325-022-02332-w","article-title":"Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"40","author":"Bindra","year":"2023","journal-title":"Adv Ther"},{"key":"2026072811150705000_13.1.e001684.37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13696998.2024.2320603","article-title":"Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates","volume":"27","author":"Elsisi","year":"2024","journal-title":"J Med Econ"},{"key":"2026072811150705000_13.1.e001684.38","first-page":"1214","article-title":"Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes","volume":"22","author":"Gonz\u00e1lez","year":"2013","journal-title":"Lupus (Los Angel)"},{"key":"2026072811150705000_13.1.e001684.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.22672"},{"key":"2026072811150705000_13.1.e001684.40","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0022-8"},{"key":"2026072811150705000_13.1.e001684.41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.50.7.490"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:14Z","timestamp":1785262514000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001684"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001684","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}